Product Data Sheet

MCE ® MedChemExpress

Cagrilintide

 Cat. No.:
 HY-P3462

 CAS No.:
 1415456-99-3

Molecular Formula: $C_{194}H_{312}N_{54}O_{59}S_2$ Molecular Weight: 4409.01

Sequence: {Eicosanedioic acid-γ-Glu}-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-

Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-As

n-Thr-Pro-NH2 (Disulfide bridge:Cys3-Cys8)

Sequence Shortening: {Eicosanedioic acid-γ-Glu}-KCNTATCATQRLAEFLRHSSNNFGPILPPTNVGSNTP-NH2 (Di

sulfide bridge:Cys3-Cys8)

Target: CGRP Receptor

Pathway: GPCR/G Protein; Neuronal Signaling

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

BIOLOGICAL ACTIVITY

Description

Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity^{[1][2][3]}.

In Vivo


Cagrilintide (compound 23) (0.1, 1, 3, 10, 30 nmol/kg; s.c.) reduces food intake in the rat^[2].

Cagrilintide (10 nmol/kg; i.v. or s.c.) shows good pharmacokinetic parameters^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	12 weeks, 400 g Sprague Dawley male rats ^[2]
Dosage:	0.1, 1, 3, 10, 30 nmol/kg
Administration:	S.c.; once for 80 h
Result:	Reduced food intake in the rat for several days at doses in the range of 1-10 nmol/kg.
Animal Model:	12 weeks, 400 g Sprague Dawley male rats ^[2]
Dosage:	10 nmol/kg
Administration:	l.v.; s.c.
Result:	Showed good pharmacokinetic parameters with $T_{1/2}$ of 20±2, 27±3 h for i.v. and s.c., respectively.

REFERENCES



Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com